Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026
Company Drug

Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia

Fineline Cube Sep 20, 2022

Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...

Company Deals Hospital

Beijing Launches HIV Precision Medicine Standardization Project

Fineline Cube Sep 20, 2022

On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...

Company Deals

Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar

Fineline Cube Sep 20, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive...

Company Deals

Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline

Fineline Cube Sep 20, 2022

China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi...

Company Medical Device

Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

Lepu Medtech Prices GDR Offering for International Expansion

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced...

Company Deals

Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D

Fineline Cube Sep 19, 2022

China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money...

Policy / Regulatory

NHSA Launches Expert Review for 2025 NRDL Update in China

Fineline Cube Sep 19, 2022

The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...

Company Drug

Daehwa Pharmaceutical Files NDA for Liporaxel in China for Gastric Cancer Treatment

Fineline Cube Sep 19, 2022

South Korea’s Daehwa Pharmaceutical (KOSDAQ: 067080) has announced the filing of a New Drug Application...

Company Drug

Antengene’s ATG-101 Receives Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Sep 19, 2022

China-based biotech Antengene Corp., Ltd (HKG: 6996) has announced that its pipeline candidate ATG-101, a...

Company Deals

Ascletis Pharma and Roche Terminate Promotion Agreement for Pegasys

Fineline Cube Sep 19, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant...

Company Deals

Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing

Fineline Cube Sep 19, 2022

Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company...

Company

Everest Medicines Appoints Rogers Yongqing Luo as New CEO

Fineline Cube Sep 19, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers...

Drug Policy / Regulatory

Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage

Fineline Cube Sep 16, 2022

Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...

Company Deals

Shenzhen Vivolight Raises RMB 100 Million in Series D1 Financing for Laser Therapy Development

Fineline Cube Sep 16, 2022

China-based laser diagnosis and treatment specialist Shenzhen Vivolight Medical Device & Technology Co., Ltd reportedly...

Company Digital

Best Covered Raises RMB 100 Million in Series A+ Funding for Cognitive Impairment Solution

Fineline Cube Sep 16, 2022

Shanghai-based digital cognitive impairment solution provider Best Covered reportedly raised RMB 100 million (USD 14.2...

Company Deals Policy / Regulatory

US Blocks Asymchem’s Acquisition of Snapdragon Chemistry

Fineline Cube Sep 16, 2022

US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...

Company Drug

Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22

Fineline Cube Sep 16, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...

Policy / Regulatory

CDE Issues Guidelines for Anti-Tumor ADC Clinical Development

Fineline Cube Sep 16, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company

Eli Lilly Announces Global C-Suite Changes, New Leadership in China

Fineline Cube Sep 16, 2022

US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...

Posts pagination

1 … 662 663 664 … 704

Recent updates

  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
  • RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal
  • Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance
  • Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint
  • China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

Company

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Company

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance

Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.